Alejandro González Veliz/LinkedIn
Jun 23, 2026, 09:36
Alejandro González Veliz: Key Takeaways from the 2026 ACC/AHA Dyslipidemia Guidelines
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn:
“Dyslipidemia management is entering a new era.
The 2026 ACC/AHA Guideline moves beyond LDL-C alone and embraces a more personalized approach to cardiovascular prevention.
- LDL-C goals are back
- Lp(a) should be measured at least once
- ApoB helps uncover residual risk
- Coronary calcium refines risk assessment
- Earlier intervention may change lifelong outcomes
The message is simple: identify risk earlier, treat smarter, and prevent ASCVD before the first event occurs.
Which update do you think will have the greatest impact on your daily practice?

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 13:27Shirley D’Sa: Connecting European and Mayo Clinic Experts in MGCS Research and Care
-
Nov 13, 2026, 13:20Josie Sirna: Representing the Thalassemia Community at Canada’s Rare Disease Conference in Halifax
-
Nov 13, 2026, 13:14Annalisa Ruggeri: 18 Years in Haematology – Celebrating a Journey at San Raffaele
-
Nov 13, 2026, 13:08Did You Know That 20–30% of Female Hemophilia Carriers Experience Bleeding Symptoms? – Haemophilia Foundation Australia
-
Nov 13, 2026, 12:12Issac Cheong: POCUS Detection of IVC Filter Thrombosis With Right Atrial Extension
-
Nov 13, 2026, 11:57Dianne E. van der Wal: Red Blood Cell Engineering and the Role of Cytokine Glycosylation
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy